facebook

Accuracap Alphagen

Scheme Rating

IME Scheme Rating

The Scheme does not meet our selection criteria at this time

Prefer other multi-cap strategies: Primarily due to the lack of return consistency in terms of the outperformance of the strategy

IME Strategy Rating

Quant Strategy: Adopts a quant strategy to construct a portfolio of 12-35 high-quality companies based on its AI-based algorithm to multi-caps.

PMS Scheme Ratings are driven by IME’s Proprietary Scheme Rating Methodology, which takes into account our ratings of the Scheme’s investment strategy, its maturity, the investment team, and our separate rating on the AMC that runs this particular scheme. Our views on each of these individual criteria are available via the IME RMS – which you can view by reaching out to one of our relationship managers (using either the live chat or book appointment feature on this site).

IME View on Accuracap Alphagen

Type: Flexi Cap | Quant | AUM (75.1 cr) | Inc Date (31 Dec 2015)

Investment Philosophy

Accuracap PMS’s Alphagen strategy is a quant-strategy that seeks to construct a portfolio of 12-35 high-quality companies (multi-cap focused) based on their Artificial Intelligence based Intelligent Ranking Algorithm. The algorithm is based on fundamental factors & risk management, with the portfolio being rebalanced once a year and stocks exited if they fall below the cut-off ranking on the Intelligent Ranking Algorithm. The average historical holding period of stocks is ~2 years.

Portfolio Construction

  • Low Churn and Tax Efficient: average holding period is 2 years. All gains are long-term capital gains. The strategy aims to be fully invested and does not attempt to time the Market
  • Portfolio Rebalancing:  rebalanced on a pre-defined schedule and usually once a year
  • Exits: exits the portfolio if the rank is below the cut-off on the rebalance date where the exiting Stock is replaced by the new high-ranked stock while keeping the number of stocks in the portfolio constant.

Trailing Performance

1yr 3yr 5yr Since Inception
Accuracap Alphagen 45.7 17.9 18.3 14.5
S&P BSE 500 TRI 39.5 19.5 19 15.6
Alpha over Broad Mkt BM 6.2 -1.6 -0.7 -1.1
Nifty 500 38.4 18.1 17.5
Alpha over Category BM 7.3 -0.2 0.8

Performance as of: 28-Feb-23 | Inception Date: 31-Dec-15

Fund Managers

Naresh Chand Gupta | 4-star rated FM

Co-founder & CEO | 34 yrs Experience | 9 yrs at current firm

Past Experience: Adobe India (MD & CEO), LNK Corp (Director-Artificial Intelligence)

Naresh is a computer scientist, researcher and corporate executive with impressive technology credentials. As CEO of Adobe India, Naresh oversaw 3500+ engineers and was responsible for over 40% of Adobe’s global R&D, including the grant of hundreds of patents. Naresh is the author of several seminal scientific papers in the area of Artificial Intelligence, Pattern Recognition, and Computer Vision and holds seven Individual U.S. Patents. He left Adobe to start Accuracap PMS in 2015, in order to use his technical expertise in algo-based quant investing.

Raman Nagpal | 4-star rated FM

Co-founder & CIO | 30 yrs Experience | 9 yrs at current firm

Past Experience: Morpria Alliance (Board of Directors), Adobe (Executive Director), AVP Technology (Founder)

Raman is a computer scientist, with a deep background in technology & finance. He has been responsible for developing several new technologies in the areas of adaptive learning engines, spurious drug detection systems and application of data analytics in stock markets. Prior to founding AccuraCap in 2015 along with Naresh Gupta, Raman worked along with him at Adobe as an Executive Director.

Fee Structure

Fee StructureFee
Fixed Fee Structure2.5
Variable Fee StructuresOption 1: 1.5% fixed + 20% above 12% hurdle
Exit Fees1yr(2%), 2yr(1%)

AMC

AMC: Accuracap PMS (click link for detailed AMC review)

Highly recommended for aggressive investors looking for high performing quant strategies: AccuraCap PMS is a highly differentiated, quant-based PMS offering with the ideal combination of a 'geek' driven core founding & investment team that have a long demonstrable track record.

AMC Rating

4 of 5 stars

AMC Pedigree

5 of 5 stars

AMC Size

3 of 5 stars

Team Pedigree

5 of 5 stars

Inv Philosophy

5 of 5 stars

Performance

4 of 5 stars

Get substantially greater insights by connecting with us!

Details shared on the public website, are only a short snapshot of the more detailed analysis that resides in our Proprietary Research Management Solution (RMS) – A proprietary cloud-based tool, that ensures that the unbiased research insights of our central research team are shared directly with investors.

Our RMS allows us to operate with a level of transparency, ethics & consistency of insights, that is unparrarelled in the industry. Our RM’s will help showcase the PMS/AIF options that are the most suited for your unique requirements.

Download Sample RMS Reports: AMC View | Scheme Comparison

Note: PMS AMC & Scheme Reviews and Ratings are based on IME Capital’s Proprietary Review and Rating Methodology (read more here: AMC Rating & Scheme Ratings). These reflect the unbiased views of our central research team, based on our assessment of the investment value of these PMS/AIF strategies for our investors. We follow a highly stringent rating-criteria, where approximately 50% of PMS AMC’s & strategies would be rated 2-star or below (this is not meant to indicate that these funds are not investment-worthy, but that they do not currently fulfill the requirements we focus on for recommending funds to our investors — based on our internal views on the merit of the AMC/strategy relative to peers). Reviews & Ratings are primarily based on research of publicly available information (SEBI disclosures, PMS websites, PMS-aggregation platforms, webinar recording, media interviews etc.) and no explicit consent is required from AMCs for the same. While we endeavour to do further due-diligence via direct interactions with the investment teams of AMCs, this is typically restricted to AMC’s that meet our foundational fund selection criteria (reviews on lower-rated AMCs are often based solely on publicly available information). The views reflected in our Reviews & Ratings, are our independent views and may not be shared by the AMC’s and the investment teams. Please read detailed disclaimer for more.